Avalo Therapeutics (AVTX) Treasury Shares (2016 - 2026)
Avalo Therapeutics (AVTX) reported Treasury Shares of $190203.0 for Q1 2026, down 54.86% on a YoY basis from $421397.0 in Q1 2025, and down 50.86% quarter-over-quarter from $387064.0 in Q4 2025.
Avalo Therapeutics (AVTX) Treasury Shares (2016 - 2026) Analysis & Trends
Avalo Therapeutics has reported Treasury Shares for 9 years, with the latest figure at $190203.0 in Q1 2026.
- For the quarter ending Q1 2026, Treasury Shares fell 54.86% year-over-year to $190203.0; the trailing twelve-month figure through Mar 2026 stood at $190203.0 (down 54.86% YoY), and the FY2025 full-year result was $387064.0, down 38.77% from the prior year.
- Treasury Shares for Q1 2026 stood at $190203.0, down from $387064.0 in the prior quarter.
- The five-year high for Treasury Shares was $632100.0 in Q3 2024, with the low at $11250.0 in Q1 2022.
- Historically, Treasury Shares has averaged $389613.5 across 4 years, with a median of $421397.0 in 2025.
- Annual changes were most pronounced in 2022 — Treasury Shares sank 92.78% — and 2025, when it plunged 33.33%.
- Avalo Therapeutics' Treasury Shares stood at $11250.0 in 2022, then surged by 5518.67% to $632100.0 in 2024, then tumbled by 38.77% to $387064.0 in 2025, then slumped by 50.86% to $190203.0 in 2026.
- The last three Treasury Shares figures came in at $190203.0 (Q1 2026), $387064.0 (Q4 2025), and $421397.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Treasury Shares (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 1.48 Mn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 700,000.00 |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Avalo Therapeutics | 295.77 Mn | 295.77 Mn | - | 190,203.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 190,203.00 |
| Mar 31, 2026 | 190,203.00 |
| Dec 31, 2025 | 387,064.00 |
| Dec 31, 2025 | 387,064.00 |
| Sep 30, 2025 | 421,397.00 |
| Sep 30, 2025 | 421,397.00 |
| Jun 30, 2025 | 421,397.00 |
| Jun 30, 2025 | 421,397.00 |
| Mar 31, 2025 | 421,397.00 |
| Mar 31, 2025 | 421,397.00 |
| Dec 31, 2024 | 632,100.00 |
| Dec 31, 2024 | 632,100.00 |
| Sep 30, 2024 | 632,100.00 |
| Sep 30, 2024 | 632,100.00 |
| Mar 31, 2022 | 11,250.00 |
| Mar 31, 2022 | 11,250.00 |
| Dec 31, 2021 | 11,250.00 |
| Dec 31, 2021 | 11,250.00 |
| Sep 30, 2021 | 77,916.00 |
| Sep 30, 2021 | 77,916.00 |